Yes, you can have PCOS without insulin resistance. While insulin resistance is extremely common in PCOS, affecting roughly 83% of lean patients and 93% of those who are overweight, it is not a universal feature of the condition. That means a meaningful minority of women with PCOS, particularly those who are lean, have normal insulin sensitivity and still experience irregular cycles, excess androgens, or polycystic ovaries.
Why PCOS Doesn’t Require Insulin Resistance
PCOS is diagnosed based on a combination of three features: irregular or absent ovulation, elevated androgens (either by blood test or visible signs like acne and excess hair growth), and polycystic ovarian morphology on ultrasound. You need two of these three to meet the widely used Rotterdam diagnostic criteria. Insulin resistance is not part of the diagnosis at all.
This matters because many women assume PCOS is fundamentally a blood sugar problem. Insulin resistance is a very common co-occurrence, and it can worsen symptoms by driving the ovaries to produce more androgens. But the condition can also be driven by other mechanisms entirely, which is why some women with perfectly normal insulin levels still develop full-blown PCOS.
What Drives PCOS When Insulin Is Normal
In women without insulin resistance, the primary driver tends to be a signaling problem in the brain. The pituitary gland releases luteinizing hormone (LH) in abnormally rapid pulses, which pushes the ovaries to overproduce androgens like testosterone. This happens independently of insulin. The excess androgens then disrupt normal follicle development, leading to the missed periods and cyst-filled ovaries that define the condition.
The adrenal glands also play a role for some women. About 20 to 30% of PCOS patients have elevated levels of DHEAS, an androgen produced almost exclusively by the adrenal glands rather than the ovaries. In one study of women aged 20 to 29, a third of PCOS patients had elevated DHEAS, and in many cases this was part of a generalized increase in androgen production across multiple sources. Interestingly, women with the most severe phenotype who had high DHEAS actually tended to have lower BMI and lower insulin levels than those with normal DHEAS, suggesting their PCOS was driven by adrenal activity rather than metabolic dysfunction.
Genetics and epigenetics round out the picture. PCOS arises from multiple gene variants interacting with environmental factors, potentially including conditions in the womb before birth. This polygenic foundation means the condition can express itself through different biological pathways in different women.
The Four PCOS Phenotypes
Not all PCOS looks the same. The Rotterdam criteria produce four recognized phenotypes, and they carry very different metabolic risk profiles:
- Phenotype A: High androgens, irregular ovulation, and polycystic ovaries. This is the “classic” full presentation and carries the highest metabolic risk.
- Phenotype B: High androgens and irregular ovulation, but normal-looking ovaries. Also considered classic PCOS with significant metabolic risk.
- Phenotype C: High androgens and polycystic ovaries, but regular ovulation. This is sometimes called “ovulatory PCOS.” Women with this phenotype tend to have lower BMI and mild or no metabolic abnormalities. They are at low risk for insulin resistance.
- Phenotype D: Irregular ovulation and polycystic ovaries, but no excess androgens. This is the mildest phenotype metabolically.
Phenotypes C and D are the ones most likely to exist without insulin resistance. If you ovulate regularly but have elevated androgens and polycystic ovaries, or if you have cycle irregularity and polycystic ovaries without androgen excess, your metabolic profile may look quite different from the “typical” PCOS patient.
Why Standard Tests Can Miss Insulin Resistance
Here’s a complication worth knowing about: some women who appear insulin-sensitive on basic testing may actually have subtle insulin resistance that standard blood work doesn’t catch. A normal fasting blood glucose does not rule out insulin resistance. In one study of lean PCOS patients, none had impaired glucose tolerance based on fasting glucose alone, but the picture changed when researchers used more detailed testing.
The most commonly used screening tool is HOMA-IR, a calculation based on fasting glucose and fasting insulin levels. In women with PCOS, a HOMA-IR score of 2.0 or above generally indicates insulin resistance, consistent with the threshold used by the European Group for the Study of Insulin Resistance. The general population often uses a cutoff of 2.5, but PCOS-specific research supports the lower threshold. A two-hour oral glucose tolerance test with insulin measurements provides a more complete picture than fasting values alone, since your body’s response to a sugar load reveals problems that fasting numbers can hide.
If you’ve only had a fasting glucose checked and were told everything looks normal, that doesn’t necessarily mean insulin resistance has been thoroughly evaluated. A fasting insulin level or HOMA-IR calculation gives a much clearer answer.
How AMH Levels Relate to Insulin Status
Anti-Müllerian hormone (AMH), often tested during fertility evaluations, turns out to have an interesting relationship with insulin resistance in PCOS. Higher AMH levels are significantly associated with lower insulin levels and lower HOMA-IR scores. As AMH rises, fasting insulin and post-meal insulin levels tend to drop. This means women with very high AMH, a hallmark of PCOS, who also have normal insulin profiles may represent a distinct subgroup where the ovarian dysfunction is driven primarily by hormonal signaling rather than metabolic issues.
Treatment Looks Different Without Insulin Resistance
If you don’t have insulin resistance, the standard approach of targeting blood sugar and insulin may not be the most effective path. Metformin, the medication most commonly associated with PCOS treatment, works primarily by improving insulin sensitivity. For women who are already insulin-sensitive, its benefits are more limited, though it can still have some effects on cycle regularity.
Myoinositol, a supplement that has gained popularity in PCOS management, offers an interesting comparison. In a randomized controlled trial comparing myoinositol to metformin, both reduced menstrual cycle length by a similar amount (nine days with myoinositol, thirteen days with metformin, with no statistically significant difference between them). But the mechanisms were different. Myoinositol’s effect on menstrual cycles was independent of body weight, sex hormones, AMH, and insulin, all of which remained unchanged during treatment. Metformin, on the other hand, improved fasting blood glucose, weight, and HDL cholesterol. For a woman without insulin resistance, myoinositol’s ability to improve cycle regularity without relying on metabolic changes could make it a reasonable option.
For women with phenotype C or D PCOS who are lean and insulin-sensitive, treatment often focuses more directly on managing specific symptoms: hormonal contraceptives for cycle regulation and androgen suppression, anti-androgen medications for acne or hair growth, or ovulation induction if fertility is the goal. The “metabolic rescue” approach that dominates PCOS discussions online simply may not apply to your situation.
What This Means for You
If you have PCOS but your insulin and glucose numbers come back normal on thorough testing, you’re not an anomaly. You likely fall into a phenotype where the condition is driven more by brain-ovary signaling or adrenal androgen production than by metabolic dysfunction. Your long-term cardiovascular and diabetes risk profile is probably more favorable than someone with insulin-resistant PCOS, though regular monitoring still makes sense since metabolic status can shift over time, particularly with weight changes or aging.
The practical takeaway is that PCOS is not one disease. It’s a spectrum of related hormonal patterns that share some features but differ in their underlying drivers and their health implications. Knowing whether insulin resistance is part of your particular picture helps you and your provider choose treatments that actually target what’s going wrong, rather than defaulting to a one-size-fits-all protocol.